Journals / Eurasian Journal of Family Medicine / 2018 / Cilt: 7 - Sayı: 3

Subclinical Hyperthyroidism: Evaluation of One Year Follow-Up

Subklinik Hipertiroidinin Bir Yıllık Seyrinin Değerlendirilmesi

Pages
85–92
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with severe subclinical hyperthyroidism should be followed up closely for more than 6 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We aimed to evaluate the possible clinical changes in subclinical hyperthyroidism determined by thyroid stimulating hormone, free triiodothyronine and free thyroxin levels during one-year follow-up.
📊
Key Findings & Data:Methods: In Haseki Treatment and Research Hospital, patients who had assessed by thyroid function tests during the first 6 months of 2014 were categorized based on their thyroid function test results. 27361 patients with either euthyroidism or subclinical hyperthyroidism were separated. 362 cases who had at least two thyroid function test results in relevance with subclinical hyperthyroidism were included in the study.
💡
Conclusion & Impact:Patients with severe subclinical hyperthyroidism should be followed up closely for more than 6 months.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: We aimed to evaluate the possible clinical changes in subclinical hyperthyroidism determined by thyroid stimulating hormone, free triiodothyronine and free thyroxin levels during one-year follow-up. Methods: In Haseki Treatment and Research Hospital, patients who had assessed by thyroid function tests during the first 6 months of 2014 were categorized based on their thyroid function test results. 27361 patients with either euthyroidism or subclinical hyperthyroidism were separated. 362 cases who had at least two thyroid function test results in relevance with subclinical hyperthyroidism were included in the study. Age range was 18 to 82 years. Those 362 patients were called by phone and asked to visit the internal diseases department for further physical examination, electrocardiogram and blood tests. Detailed anamnesis and physical examination findings were recorded in 38 patients who visited the hospital on our call. Thyroid ultrasonography results, operation and drug use history were evaluated. Results: Patients were divided into three groups according to thyroid stimulating hormone values: euthyroid, mild subclinical hyperthyroidism and severe subclinical hyperthyroidism. Age, gender and metabolic parameters were evaluated. Between groups there were statistically significant differences regarding age, gender, blood glucose, blood cholesterol and LDL values. Disease progression to clinical hyperthyroidism was statistically significant, especially in patients followed for more than 6 months. Conclusion: Early treatment of subclinical hyperthyroidism is important in order to prevent its possible cardiac and osteoporotic complications. Patients with severe subclinical hyperthyroidism should be followed up closely for more than 6 months.

Özet

Amaç: Çalışmamızda tiroid stimülan hormon, serbest triiodotironin, serbest tiroksin değerlerine göre subklinik hipertiroidi saptanan hastaların bir yıllık takip süreci boyunca klinik durumlarında gözlenecek olası değişiklikleri değerlendirmeyi amaçladık. Yöntem: Araştırmaya Haseki Eğitim ve Araştırma Hastanesi’ne 2014 yılının ilk 6 ayı içinde tiroid fonksiyon testi bakılmış vakalar dahil edildi. Bu vakalar laboratuar sonuçlarına göre kategorize edildi; ötiroid ve subklinik hipertiroidi düşünülen 27361 vaka ayrıldı. Bu laboratuar sonuçlarında subklinik hipertiroidiyle uyumlu en az iki tetkiki olan 18-82 yaş arası 362 hastanın verileri temel olarak değerlendirildi. Değerlendirilen 362 hasta telefonla aranarak fizik muayene, elektrokardiyografi ve kan tahlili yapılmak üzere hastanemizin dahiliye servisine çağırıldı. Hastaneye gelen 38 hastanın detaylı anamnezleri alınıp fizik muayeneleri yapıldı. Tiroid ultrasonografi sonuçları, operasyon ve ilaç kullanım öyküleri değerlendirildi. Bulgular: Tiroid stimulan hormon değerlerine göre ötiroid, hafif subklinik hipertiroidi ve ağır subklinik hipertirodi şeklinde 3 gruba ayrılan hastalar yaş, cinsiyet ve metabolik parametrelerine göre değerlendirildi. Gruplar arasında yaş, cinsiyet, glikoz, kolesterol ve LDL kolesterol değerleri arasında anlamlı fark bulundu. Takip süresi 6 aydan fazla olan hastalarda aşikar hipertiroidiye gidiş anlamlıydı.Sonuç: Subklinik hipertiroidi vakalarının erken tedavisi kardiyak ve kemik komplikasyonlarını önlemek açısından önemlidir. Ağır subklinik hipertiroidi vakaları özellikle aşikar tiroid hastalığı gelişmesi açısından dikkatle ve altı aydan uzun süre izlenmelidir.

🔖

Cite This Article

ATAOĞLU, H. E., SEZER, B. T., ÇAKMAK, S. (2022). Subclinical Hyperthyroidism: Evaluation of One Year Follow-Up. Eurasian Journal of Family Medicine, Cilt: 7 - Sayı: 3, 85–92. https://ajindex.com/articles/508379

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Martin I. Surks MD, Eduardo Ortiz MD MPH, Gilbert H. Daniels MD et al. Subclinical thyroid disease scientific review and guidelines for diagnosis and management. JAMA 2004;291(2):228-38. doi: 10,1001 / jama.291.2.228. Fatourechi V. Subclinical thyrod disease. Mayo Clin Proc 2001;76(4):413-7.
  2. Biondi B, Bartalena L, Cooper DS, Heqedüs L, Laurberg P, Kahaly GJ. The 2015 European thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 2015;4(3):149–63. doi: 10.1159/000438750. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005;152(1):1-9. Woeber KA. Subclinical thyroid dysfunction. Arch Intern Med 1997;157(10):1065-8.
  3. Helfand M., Redfern CC. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann Intern Med 1998;129(2):144-58.
  4. Canaris GJ, Manovitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch of Intern Med 2000;160(4):526– 34. Pamuk G, İlhan MM. Subklinik hipertiroidi. Smyrna Tıp Dergisi 2015;5(3):52-7. De Whalley P. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyr- oxine in one general practice. Br J Gen Pract 1995;45(391):93-5.
  5. Stott DJ, McLellan AR, Finlayson J, Chu P, Alexander WD. Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at risk of developing overt hyperthyroidism. Q J Med 1991;78(285):77-84.
  6. Belfiore A, Sava L, Runello F, Tomaselli L, Vigneri R. Solitary autonomously functioning thyroid nodules and iodine deficiency. J Clin Endocrinol Metab 1983;56(2):283-7.
  7. Aghini-Lombardi F, Antonangeli L, Martino E, Vitti P, Maccherini D, Leoli F, et al. The spectrum of thyroid disease in an iodine- deficient community: the Pescopagano survey. J Clin Endocrinol Metab 1999;84(2):561–6. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992;327(2):94-8.
  8. Ayres J, Rees J, Clark TJ, Maisey MN. Thyrotoxicosis and dyspnoea. Clin Endocrinol (Oxf) 1982;16(1):65-71.
  9. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, et al. Cardiac function, physical exercise capasity, and quality of life during long-term thyrotropinsuppressive therapy with levothyroxin: effect of individual dose tailoring. J Clin Endocrinol Metab 2000;85(1):159-64.
  10. Parle JV, Maisonneuve, P, Sheppard, MC, B